Skip to main content
Fig. 3 | Journal of Ovarian Research

Fig. 3

From: Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer

Fig. 3

Strong synergy with APR-246 and cisplatin (a), carboplatin (b), or doxorubicin (c) in primary ovarian cancer cells. Cell viability was assessed by FMCA assay after 72 h incubation with drugs. Additive model was used for analysis of combination effects. Combination Index (CI) values are presented above the bars. CI < 0.8 indicates synergy and < 0.5 strong synergy. CI values < 0.8 are marked in red. The results shown are mean ± SEM (n = 2)

Back to article page

Journal of Ovarian Research

ISSN: 1757-2215

Contact us